Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.
Animals
Antiviral Agents
/ pharmacology
Betacoronavirus
/ drug effects
Cell Line
Cell Line, Tumor
Cells, Cultured
Coronavirus OC43, Human
/ drug effects
Endoplasmic Reticulum Stress
Humans
Influenza A Virus, H1N1 Subtype
/ drug effects
Mice
Microbial Sensitivity Tests
Orthomyxoviridae Infections
/ drug therapy
Respiratory Syncytial Virus, Human
/ drug effects
Ribavirin
/ pharmacology
SARS-CoV-2
/ drug effects
Thapsigargin
/ pharmacology
Virus Replication
/ drug effects
SARS-CoV-2
antiviral
broad-spectrum
coronavirus OC43
influenza virus
inhibitor
innate immunity
mouse
oseltamivir
remdesivir
respiratory syncytial virus
ribavirin
thapsigargin
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
03 02 2021
03 02 2021
Historique:
received:
14
01
2021
revised:
23
01
2021
accepted:
26
01
2021
entrez:
6
2
2021
pubmed:
7
2
2021
medline:
18
2
2021
Statut:
epublish
Résumé
The long-term control strategy of SARS-CoV-2 and other major respiratory viruses needs to include antivirals to treat acute infections, in addition to the judicious use of effective vaccines. Whilst COVID-19 vaccines are being rolled out for mass vaccination, the modest number of antivirals in use or development for any disease bears testament to the challenges of antiviral development. We recently showed that non-cytotoxic levels of thapsigargin (TG), an inhibitor of the sarcoplasmic/endoplasmic reticulum (ER) Ca
Identifiants
pubmed: 33546185
pii: v13020234
doi: 10.3390/v13020234
pmc: PMC7913267
pii:
doi:
Substances chimiques
Antiviral Agents
0
Ribavirin
49717AWG6K
Thapsigargin
67526-95-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MC_PC_18058
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M008770/1
Pays : United Kingdom
Références
J Biol Chem. 1991 Sep 15;266(26):17067-71
pubmed: 1832668
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Methods Mol Biol. 2016;1442:33-40
pubmed: 27464685
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
Nat Commun. 2021 Sep 20;12(1):5536
pubmed: 34545074
Front Immunol. 2018 Jul 20;9:1581
pubmed: 30079062
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
Clinicoecon Outcomes Res. 2014 Apr 25;6:217-25
pubmed: 24812523
J Virol Methods. 2003 Feb;107(2):205-12
pubmed: 12505635
Influenza Other Respir Viruses. 2018 Mar;12(2):267-278
pubmed: 29265727
J Antimicrob Chemother. 2018 Jul 1;73(7):1823-1829
pubmed: 29596680
Nat Rev Dis Primers. 2018 Jun 28;4(1):3
pubmed: 29955068
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Curr Top Microbiol Immunol. 2013;372:3-38
pubmed: 24362682
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11613-11618
pubmed: 30352857
Viruses. 2020 Dec 10;12(12):
pubmed: 33322045
Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21
pubmed: 19506054
Infect Drug Resist. 2017 Apr 20;10:121-134
pubmed: 28458567
Viruses. 2020 Sep 27;12(10):
pubmed: 32992478
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Nat Rev Microbiol. 2019 Apr;17(4):233-245
pubmed: 30723301
Nat Microbiol. 2020 Jan;5(1):27-33
pubmed: 31768027
Nature. 2020 Oct;586(7827):113-119
pubmed: 32707573
Front Microbiol. 2020 Aug 13;11:1818
pubmed: 32903349